RT Journal Article
SR Electronic
T1 INTESTINAL GLUCONEOGENESIS IS DOWNREGULATED IN PAEDIATRIC PATIENTS WITH COELIAC DISEASE
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.08.21262795
DO 10.1101/2021.09.08.21262795
A1 Karlson, Olof
A1 Arnell, Henrik
A1 Gudjonsdottir, Audur H.
A1 Agardh, Daniel
A1 Naluai, Åsa Torinsson
YR 2021
UL http://medrxiv.org/content/early/2021/09/14/2021.09.08.21262795.abstract
AB Objective Untreated coeliac disease (CD) patients have increased levels of blood glutamine and a lower duodenal expression of glutaminase (GLS). Intestinal gluconeogenesis (IGN) is a process through which glutamine is turned into glucose in the small intestine, for which GLS is crucial. Animal studies suggest impaired IGN may have long-term effects on metabolic control and be associated with development of type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). The aim of this study was to thoroughly investigate IGN at the gene expression level in children with untreated coeliac disease.Design Quantitative polymerase chain reaction (qPCR) was used to quantify expression of 11 target genes related to IGN using the delta-delta Ct method with three reference genes (GUSB, IPO8 and YWHAZ) in duodenal biopsies collected from 84 children with untreated coeliac disease and 58 disease controls.Results Significantly lower expression of nine target genes involved in IGN was seen in duodenal biopsies from CD patients compared with controls: FBP1, G6PC, GLS, GPT1, PCK1, PPARGC1A, SLC2A2, SLC5A1, and SLC6A19. No significant differences in expression were seen for G6PC3 and GOT1.Conclusion Children with untreated coeliac disease have lower expression of genes important for IGN. Further studies are warranted to disentangle whether this is a consequence of intestinal inflammation or due to an impaired metabolic pathway shared with other chronic metabolic diseases. Impaired IGN could be a mechanism behind the increased risk of NAFLD seen in CD patients.What is already known about this subject?Genome-wide association studies have shown an association between coeliac disease (CD) and glutaminase (GLS).Intestinal gluconeogenesis (IGN) is a process with a recently described important function in energy homeostasis and metabolic disease. GLS is critical for IGN by enabling it to use glutamine, its main substrate.CD patients are at an increased risk of non-alcoholic fatty liver disease (NAFLD) as adults.What are the new findings?Nine genes involved in IGN are downregulated at the gene expression level in the small intestine of children with untreated CD, suggesting impairment of IGN.How might it impact on clinical practice in the foreseeable future?Impaired IGN might be a mechanism behind the increased risk of NAFLD seen in CD patients as adults.Early diagnosis and treatment of CD may restore IGN and prevent CD patients from NAFLD later in adulthood.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by Swedish Research Council, Grant/Award No.: 2018-02553, the Swedish Coeliac Society, the Swedish Society of Medicine, Bengt Ihre's Forskningsfond, Gastroenterologisk forskningsfond, Stiftelsen Professor Nanna Svartz Fond, Tore Nilsons Fond, Ake Wibergs Stiftelse, the Royal Physiographic Society of Lund, Stiftelsen Apotekare Hedbergs fond, and Ruth and Richard Julin Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Regional Ethics Review Board in Gothenburg approved the study. All guardians and study participants (when appropriate) gave their written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, [ATN], upon reasonable request.